An Open-label, Single-dose Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Identification of Metabolite Structures for [14C]-CORT125134 in Healthy Subjects
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Relacorilant (Primary)
- Indications Alcoholism; Cushing syndrome; Solid tumours
- Focus Pharmacokinetics
- Sponsors Corcept Therapeutics
- 03 Mar 2017 New trial record